How new technologies are creating new marketsSarah Rickwood looks at why the next frontier for pharmaceutical innovation may not be a pharmaceutical at all, Share XHow new technologies are creating new marketshttps://deep-dive.pharmaphorum.com/magazine/sales-and-marketing-2019/how-new-technologies-are-creating-new-markets-iqvia-launch/
IQVIA launches UK cancer database amid survival rate concernAs figures show the UK continues to lag behind other developed countries in cancer survival, a new project Share XIQVIA launches UK cancer database amid survival rate concernhttps://pharmaphorum.com/news/iqvia-launches-uk-national-cancer-database-amid-concerns-over-survival-rates/
Achieving launch excellence in orphan medicinesNew rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking Share XAchieving launch excellence in orphan medicineshttps://pharmaphorum.com/market-access-2/achieving-launch-excellence-in-orphan-medicines/
Launch excellence in a disrupted world – challenges & opportunitiesOverview The launch environment has undergone huge changes as the pharmaceutical industry’s focus has moved from primary care Share XLaunch excellence in a disrupted world – challenges & opportunitieshttps://pharmaphorum.com/market-access-2/launch-excellence-in-a-disrupted-world-challenges-opportunities/
Orphan medicines launch excellence: sustaining launch successOverview Launching orphan medicines excellently will become even more important over the next five years as more patients Share XOrphan medicines launch excellence: sustaining launch successhttps://pharmaphorum.com/market-access-2/orphan-medicines-launch-excellence-sustaining-launch-success/
Simulated data, real-world patient insightsThe UK has some of the best patient data available anywhere in the world, and a preeminent position in Share XSimulated data, real-world patient insightshttps://pharmaphorum.com/views-and-analysis/simulated-data-real-world-patient-insights/
Biotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?Drug development can be quite a risky business at the best of times, but particularly in the biotech Share XBiotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?https://pharmaphorum.com/views-and-analysis/biotech-in-post-brexit-britain-the-future-for-the-uks-pharma-innovation-engine/
The 2nd Life Sciences Sector Deal and the NHS 10 Year PlanOverview Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK Share XThe 2nd Life Sciences Sector Deal and the NHS 10 Year Planhttps://pharmaphorum.com/market-access-2/the-2nd-life-sciences-sector-deal-and-the-nhs-10-year-plan/
UCB, Roche, and IQVIA take lead in UK life sciences investmentPharma giant UCB is to invest around £1 billion in the UK as part of a second life Share XUCB, Roche, and IQVIA take lead in UK life sciences investmenthttps://pharmaphorum.com/news/ucb-roche-and-iqvia-take-lead-in-uk-life-sciences-investment/
